New drug cocktail aims to boost radiation for early lung cancer
NCT ID NCT07379398
First seen Feb 01, 2026
Summary
This phase 2 trial tests whether adding an experimental immunotherapy (iparomlimab and tuvonralimab) to targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 people with stage I-IIB disease will receive the drug every 3 weeks for a year, starting right after their first radiation session. The study looks at how long patients stay cancer-free and how safe the combination is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab injection (a combination antibody targeting PD-1 and CTLA-4) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this could offer a new treatment option for early-stage non-small cell lung cancer that may improve outcomes compared to radiation alone.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The combination of immunotherapy and radiation can cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.